CN1020944C
(zh)
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
US6515117B2
(en)
*
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
JP4822039B2
(ja)
*
|
1999-12-28 |
2011-11-24 |
味の素株式会社 |
経口投与用糖尿病薬製剤
|
US6627611B2
(en)
*
|
2000-02-02 |
2003-09-30 |
Kotobuki Pharmaceutical Co Ltd |
C-glycosides and preparation of thereof as antidiabetic agents
|
FR2809310B1
(fr)
*
|
2000-05-26 |
2004-02-13 |
Centre Nat Rech Scient |
Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
|
EP1333887B1
(en)
*
|
2000-10-30 |
2006-08-02 |
Ortho-McNeil Pharmaceutical, Inc. |
Combination therapy comprising anti-diabetic and anticonvulsant agents
|
US20030032675A1
(en)
*
|
2001-02-15 |
2003-02-13 |
Franz G. Andrew |
Manufacture of thyroid hormone tablets having consistent active moiety amounts
|
US20030224047A1
(en)
*
|
2001-02-15 |
2003-12-04 |
Franz G. Andrew |
Levothyroxine compositions and methods
|
BR0207297A
(pt)
*
|
2001-02-15 |
2005-04-19 |
King Pharmaceuticals Inc |
Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
|
US6555581B1
(en)
|
2001-02-15 |
2003-04-29 |
Jones Pharma, Inc. |
Levothyroxine compositions and methods
|
US6936590B2
(en)
*
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
US20030045553A1
(en)
*
|
2001-04-04 |
2003-03-06 |
Bussolari Jacqueline C. |
Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
|
WO2002083066A2
(en)
*
|
2001-04-11 |
2002-10-24 |
Bristol-Myers Squibb Company |
Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
|
WO2003011880A1
(fr)
*
|
2001-07-31 |
2003-02-13 |
Kissei Pharmaceutical Co., Ltd. |
Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
|
US20030198667A1
(en)
*
|
2001-08-10 |
2003-10-23 |
Franz Andrew G. |
Methods of producing dispersible pharmaceutical compositions
|
US20030180353A1
(en)
*
|
2001-08-10 |
2003-09-25 |
Franz G. Andrew |
Stabilized pharmaceutical compositions
|
US20030190349A1
(en)
*
|
2001-08-10 |
2003-10-09 |
Franz G. Andrew |
Methods of stabilizing pharmaceutical compositions
|
US20030199587A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique Cmax properties
|
US20030203967A1
(en)
*
|
2001-08-14 |
2003-10-30 |
Franz G. Andrew |
Levothyroxine compositions having unique Tmax properties
|
US20030195253A1
(en)
*
|
2001-08-14 |
2003-10-16 |
Franz G. Andrew |
Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
|
US20030199586A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Unique levothyroxine aqueous materials
|
US20030198672A1
(en)
*
|
2001-08-14 |
2003-10-23 |
Franz G. Andrew |
Levothyroxine compositions having unique triidothyronine plasma AUC properties
|
US20030181524A1
(en)
*
|
2001-10-29 |
2003-09-25 |
Franz G. Andrew |
Levothyroxine compositions having unique triiodothyronine Tmax properties
|
US6806381B2
(en)
*
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
EP1443919A4
(en)
*
|
2001-11-16 |
2006-03-22 |
Bristol Myers Squibb Co |
DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AU2002351752A1
(en)
|
2001-12-29 |
2003-07-30 |
Novo Nordisk A/S |
Combined use of a glp-1 compound and another drug for treating dyslipidemia
|
CA2481371A1
(en)
*
|
2002-03-11 |
2003-09-18 |
Peter Zahradka |
Use of ppar alpha agonists for the treatment of vascular and renal diseases
|
US20050215489A1
(en)
*
|
2002-03-14 |
2005-09-29 |
Bayer Pharmaceuticals Corporation |
Methods of treating diabetes using pde 11a inhibitors
|
WO2003090783A1
(fr)
*
|
2002-04-26 |
2003-11-06 |
Ajinomoto Co., Inc. |
Agent preventif/remede pour diabete
|
US7956041B2
(en)
|
2002-04-26 |
2011-06-07 |
Ajinomoto Co., Inc. |
Prophylactic and therapeutic agent of diabetes mellitus
|
US7057046B2
(en)
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
TWI254635B
(en)
*
|
2002-08-05 |
2006-05-11 |
Yamanouchi Pharma Co Ltd |
Azulene derivative and salt thereof
|
WO2004031203A1
(ja)
*
|
2002-10-04 |
2004-04-15 |
Kissei Pharmaceutical Co., Ltd. |
ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
DE10258008B4
(de)
*
|
2002-12-12 |
2006-02-02 |
Sanofi-Aventis Deutschland Gmbh |
Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
DE10258007B4
(de)
*
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
US7375213B2
(en)
|
2003-01-03 |
2008-05-20 |
Bristol-Myers Squibb Company |
Methods of producing C-aryl glucoside SGLT2 inhibitors
|
EP1457206A1
(en)
*
|
2003-03-13 |
2004-09-15 |
Fournier Laboratories Ireland Limited |
Combined use of a fibrate and orlistat for the treatment of obesity
|
KR101001848B1
(ko)
*
|
2003-03-14 |
2010-12-17 |
고토부키 세이야쿠 가부시키가이샤 |
C-글리코시드 유도체 또는 이의 염, 및 이를 포함하는 의약 조성물
|
JP2004300102A
(ja)
*
|
2003-03-31 |
2004-10-28 |
Kissei Pharmaceut Co Ltd |
縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
|
WO2004096278A1
(ja)
*
|
2003-04-28 |
2004-11-11 |
Sankyo Company, Limited |
アディポネクチン産生増強剤
|
CA2524175C
(en)
*
|
2003-04-28 |
2016-06-14 |
Sankyo Company Limited |
Sugar intake-ability enhancer
|
US7459474B2
(en)
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
UA86042C2
(en)
|
2003-08-01 |
2009-03-25 |
Янссен Фармацевтика Н.В. |
Substituted indazole-o-glucosides
|
US8785403B2
(en)
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
WO2005011592A2
(en)
*
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica N.V. |
Substituted indazole-o-glucosides
|
ME00411B
(me)
|
2003-08-01 |
2011-10-10 |
Tanabe Seiyaku Co |
Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavistan od natrijuma
|
AR048282A1
(es)
|
2003-08-01 |
2006-04-19 |
Janssen Pharmaceutica Nv |
Indol- o - glucosidos sustituidos
|
US7094763B2
(en)
|
2003-08-01 |
2006-08-22 |
Janssen Pharaceutica, N.V. |
Substituted fused heterocyclic C-glycosides
|
EP1679966A4
(en)
|
2003-08-01 |
2009-05-27 |
Janssen Pharmaceutica Nv |
BENZIMIDAZOLE-, BENZTRIAZOLE- AND BENZIMIDAZOLONE-SUBSTITUTED O-GLUCOSIDES
|
US7375090B2
(en)
|
2003-08-26 |
2008-05-20 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
|
US20050054731A1
(en)
*
|
2003-09-08 |
2005-03-10 |
Franco Folli |
Multi-system therapy for diabetes, the metabolic syndrome and obesity
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
GB0322552D0
(en)
|
2003-09-26 |
2003-10-29 |
Astrazeneca Uk Ltd |
Therapeutic treatment
|
EP1687410A4
(en)
*
|
2003-10-07 |
2008-04-09 |
Isis Pharmaceuticals Inc |
ANTISENSE OLIGONUCLEOTIDES OPTIMIZED TO TARGET THE KIDNEY
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
US7674913B2
(en)
|
2003-11-12 |
2010-03-09 |
Phenomix Corporation |
Heterocyclic boronic acid compounds
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
EP1581246B1
(en)
*
|
2003-12-17 |
2013-01-16 |
Amylin Pharmaceuticals, LLC |
Compositions for the treatment and prevention of nephropathy
|
JP2006514649A
(ja)
*
|
2003-12-17 |
2006-05-11 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
腎症の治療および予防のための組成物
|
US7371732B2
(en)
*
|
2003-12-22 |
2008-05-13 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
|
RU2387663C2
(ru)
*
|
2004-03-04 |
2010-04-27 |
Киссеи Фармасьютикал Ко., Лтд. |
Конденсированные гетероциклические производные, содержащие их медицинские композиции и их медицинское применение
|
JP4950657B2
(ja)
*
|
2004-03-04 |
2012-06-13 |
キッセイ薬品工業株式会社 |
縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
|
CN103030617A
(zh)
*
|
2004-03-16 |
2013-04-10 |
贝林格尔.英格海姆国际有限公司 |
吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
|
EP1731524A4
(en)
*
|
2004-03-31 |
2009-05-20 |
Kissei Pharmaceutical |
PHENOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE, AND ITS MEDICINAL USE
|
JPWO2005095372A1
(ja)
*
|
2004-03-31 |
2008-02-21 |
キッセイ薬品工業株式会社 |
ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途
|
JPWO2005095373A1
(ja)
*
|
2004-03-31 |
2008-02-21 |
キッセイ薬品工業株式会社 |
ナフタレン誘導体、それを含有する医薬組成物およびその医薬用途
|
CA2568640C
(en)
|
2004-06-04 |
2011-08-09 |
Teva Pharmaceutical Industries Ltd. |
Pharmaceutical composition containing irbesartan
|
DE102004028241B4
(de)
*
|
2004-06-11 |
2007-09-13 |
Sanofi-Aventis Deutschland Gmbh |
Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
|
US7393836B2
(en)
|
2004-07-06 |
2008-07-01 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
CN1984898A
(zh)
*
|
2004-07-08 |
2007-06-20 |
安斯泰来制药有限公司 |
生产薁衍生物的方法和合成该薁衍生物的中间体
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
US20080045466A1
(en)
|
2004-07-21 |
2008-02-21 |
Kenji Katsuno |
Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat
|
TW200606129A
(en)
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
JP2008508213A
(ja)
*
|
2004-07-27 |
2008-03-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
D−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法
|
WO2006018150A1
(de)
*
|
2004-08-11 |
2006-02-23 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
JP5046370B2
(ja)
*
|
2004-09-29 |
2012-10-10 |
キッセイ薬品工業株式会社 |
1−(β−D−グリコピラノシル)−3−置換含窒素ヘテロ環化合物、それを含有する医薬組成物及びその医薬用途
|
DE102004048388A1
(de)
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
EP1828216B1
(en)
|
2004-12-16 |
2008-09-10 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
TW200637839A
(en)
|
2005-01-07 |
2006-11-01 |
Taisho Pharmaceutical Co Ltd |
1-thio-d-glucitol derivatives
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
CN101111508B
(zh)
*
|
2005-01-28 |
2011-03-30 |
中外制药株式会社 |
螺缩酮衍生物及其作为糖尿病治疗药物的用途
|
MY147375A
(en)
|
2005-01-31 |
2012-11-30 |
Mitsubishi Tanabe Pharma Corp |
Indole derivatives
|
JP4496174B2
(ja)
*
|
2005-01-31 |
2010-07-07 |
田辺三菱製薬株式会社 |
医薬組成物
|
AR053329A1
(es)
|
2005-01-31 |
2007-05-02 |
Tanabe Seiyaku Co |
Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
|
US7238702B2
(en)
*
|
2005-02-10 |
2007-07-03 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones as 5HT modulators
|
ES2334940T3
(es)
*
|
2005-02-23 |
2010-03-17 |
Boehringer Ingelheim International Gmbh |
Derivados de ((hetero)ariletinilbencil)benceno sustituidos con glucopiranosilo y uso de los mismos como inhibidores del cotransportador 2 de glucosa dependiente de sodio (sglt2).
|
EP1865913A1
(en)
*
|
2005-03-11 |
2007-12-19 |
Elixir Pharmaceuticals, Inc. |
Sirt inhibitors that bind to nad
|
US20060235028A1
(en)
|
2005-04-14 |
2006-10-19 |
Li James J |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
WO2006108842A1
(en)
*
|
2005-04-15 |
2006-10-19 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
|
US7723309B2
(en)
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
UA91546C2
(uk)
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
TW200726746A
(en)
*
|
2005-05-06 |
2007-07-16 |
Microbia Inc |
Processes for production of 4-biphenylylazetidin-2-ones
|
US7772191B2
(en)
*
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
WO2007000445A1
(en)
*
|
2005-06-29 |
2007-01-04 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
TW200726755A
(en)
*
|
2005-07-07 |
2007-07-16 |
Astellas Pharma Inc |
A crystalline choline salt of an azulene derivative
|
EP1906934A4
(en)
*
|
2005-07-14 |
2012-03-07 |
Franco Folli |
DAILY DOSAGE SCHEME FOR THE TREATMENT OF DIABETES, OBESITY, METABOLIC SYNDROME AND POLYKYSTIC OVAIRE SYNDROME
|
ATE468347T1
(de)
*
|
2005-07-27 |
2010-06-15 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituierte ((hetero)cycloalyklethynyl-benzyl)- benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters (sglt)
|
CA2617102A1
(en)
*
|
2005-07-28 |
2007-02-08 |
Bristol-Myers Squibb Company |
Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
DE602006017566D1
(de)
*
|
2005-08-30 |
2010-11-25 |
Boehringer Ingelheim Pharma |
Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
|
CA2621314A1
(en)
|
2005-09-08 |
2007-03-15 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(.beta.-d-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
AR056195A1
(es)
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
JP2009531291A
(ja)
|
2006-02-15 |
2009-09-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換ベンゾニトリル誘導体、それらの化合物を含有する医薬組成物、それらの使用及び製造方法
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
PE20080697A1
(es)
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
TW200812995A
(en)
*
|
2006-05-19 |
2008-03-16 |
Taisho Pharmaceutical Co Ltd |
C-phenyl glycitol compound
|
JP5230613B2
(ja)
*
|
2006-05-23 |
2013-07-10 |
テラコス・インコーポレイテッド |
グルコース輸送体阻害剤およびその使用方法
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
BRPI0713058A2
(pt)
*
|
2006-06-29 |
2012-04-10 |
Taisho Pharmaceutical Co., Ltd. |
composto de 1-tioglucitol de c-fenila
|
US8318941B2
(en)
|
2006-07-06 |
2012-11-27 |
Bristol-Myers Squibb Company |
Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
US7910747B2
(en)
|
2006-07-06 |
2011-03-22 |
Bristol-Myers Squibb Company |
Phosphonate and phosphinate pyrazolylamide glucokinase activators
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
TWI403516B
(zh)
|
2006-07-27 |
2013-08-01 |
Chugai Pharmaceutical Co Ltd |
To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
|
TWI418556B
(zh)
|
2006-07-27 |
2013-12-11 |
Mitsubishi Tanabe Pharma Corp |
吲哚衍生物
|
TWI432446B
(zh)
|
2006-07-27 |
2014-04-01 |
Chugai Pharmaceutical Co Ltd |
稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
|
US8039441B2
(en)
|
2006-08-15 |
2011-10-18 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
EP2074130A1
(en)
*
|
2006-09-21 |
2009-07-01 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
TWI499414B
(zh)
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
|
US20100093744A1
(en)
|
2006-10-13 |
2010-04-15 |
Chugai Seiyaku Kabushiki Kaisha |
Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes
|
CA2667550A1
(en)
|
2006-10-27 |
2008-05-02 |
Boehringer Ingelheim International Gmbh |
Crystalline form of 4-(.beta.-d-glucopyranos-1-yl)-1-methyl-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
UY30730A1
(es)
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
CA2671699C
(en)
|
2006-12-04 |
2014-07-08 |
Janssen Pharmaceutica N.V. |
Thienyl-containing glycopyranosyl derivatives as antidiabetics
|
US8101634B2
(en)
|
2006-12-06 |
2012-01-24 |
Glaxosmithkline Llc |
Bicyclic compounds and use as antidiabetics
|
CN101568537A
(zh)
|
2006-12-21 |
2009-10-28 |
安斯泰来制药有限公司 |
C-糖苷衍生物的制造方法及其合成中间体
|
US7795228B2
(en)
*
|
2006-12-28 |
2010-09-14 |
Theracos, Inc. |
Spiroheterocyclic glycosides and methods of use
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
EP2125768A1
(en)
*
|
2007-02-21 |
2009-12-02 |
Boehringer Ingelheim International GmbH |
Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
WO2008109591A1
(en)
*
|
2007-03-08 |
2008-09-12 |
Lexicon Pharmaceuticals, Inc. |
Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
|
TW200904454A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
|
TW200904405A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Pharmaceutical formulations containing an SGLT2 inhibitor
|
AR065913A1
(es)
|
2007-04-02 |
2009-07-08 |
Theracos Inc |
Derivados de glicosido bencilico, composicion y combinacion farmaceutica y uso
|
US8546394B2
(en)
|
2007-04-17 |
2013-10-01 |
Bristol-Myers Squibb Company |
Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
JP2010528023A
(ja)
*
|
2007-05-18 |
2010-08-19 |
ブリストル−マイヤーズ スクイブ カンパニー |
Sglt2阻害剤の結晶構造およびその製造方法
|
JP5546451B2
(ja)
|
2007-06-04 |
2014-07-09 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
US8383609B2
(en)
|
2007-07-05 |
2013-02-26 |
Centre National De La Recherche Scientifique |
Phosphorus containing heterocyclic compounds, sugar analogues, and compositions having anti-cancer activity containing the same
|
CN103254119B
(zh)
*
|
2007-07-10 |
2016-07-06 |
莱西肯医药有限公司 |
钠-葡萄糖协同转运蛋白2的抑制剂及其用法
|
DK2183263T3
(da)
|
2007-07-26 |
2012-01-30 |
Lexicon Pharmaceuticals Inc |
Fremgangsmåder og forbindelser anvendelige til fremstilling af natriumglucose-cotransportør-2-inhibitorer
|
ES2408384T3
(es)
*
|
2007-07-27 |
2013-06-20 |
Bristol-Myers Squibb Company |
Nuevos activadores de glucoquinasa y procedimientos de uso de los mismos
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
JP4809931B2
(ja)
|
2007-08-23 |
2011-11-09 |
セラコス・インコーポレイテッド |
ベンジルベンゼン誘導体およびその使用方法
|
CN101801371B
(zh)
|
2007-09-10 |
2012-11-28 |
詹森药业有限公司 |
可用作sglt抑制剂的化合物的制备方法
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
CN101503399B
(zh)
*
|
2008-02-04 |
2012-06-27 |
白鹭医药技术(上海)有限公司 |
C-芳基葡萄糖苷sglt2抑制剂
|
WO2009117367A1
(en)
*
|
2008-03-18 |
2009-09-24 |
Bristol-Myers Squibb Company |
Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof
|
FR2929615B1
(fr)
*
|
2008-04-02 |
2010-12-17 |
Tfchem |
Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
|
DE102008017590A1
(de)
*
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
WO2009143020A1
(en)
|
2008-05-22 |
2009-11-26 |
Bristol-Myers Squibb Company |
Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
|
AU2009256157B2
(en)
|
2008-06-04 |
2014-12-18 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
BRPI0916769A2
(pt)
*
|
2008-07-15 |
2017-09-26 |
Theracos Inc |
derivados de benzilbenzeno deuterados e métodos de uso
|
WO2010009319A2
(en)
|
2008-07-16 |
2010-01-21 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
US8283454B2
(en)
|
2008-08-22 |
2012-10-09 |
Theracos, Inc. |
Processes for the preparation of SGLT2 inhibitors
|
ES2380408T3
(es)
*
|
2008-08-28 |
2012-05-11 |
Pfizer Inc. |
Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
MA33044B1
(fr)
|
2009-02-13 |
2012-02-01 |
Boehringer Ingelheim Int |
Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient
|
SG173587A1
(en)
|
2009-02-13 |
2011-09-29 |
Boehringer Ingelheim Int |
Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
PL2395983T3
(pl)
|
2009-02-13 |
2020-09-07 |
Boehringer Ingelheim International Gmbh |
Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
|
US8278316B2
(en)
|
2009-03-09 |
2012-10-02 |
Bristol-Myers Squibb Company |
Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
|
US8563583B2
(en)
|
2009-03-09 |
2013-10-22 |
Bristol-Myers Squibb Company |
Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
|
US8685934B2
(en)
*
|
2009-05-27 |
2014-04-01 |
Bristol-Myers Squibb Company |
Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
|
US20110009347A1
(en)
*
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
SI2451797T1
(sl)
|
2009-07-10 |
2013-07-31 |
Janssen Pharmaceutica, N.V. |
Postopek kristalizacije 1-(beta-d-glukopiranosil)-4-metil-3-(5-(4-fluorofenil)-2-tienilmetil) benzena
|
CN102574829B
(zh)
|
2009-09-30 |
2015-07-01 |
贝林格尔.英格海姆国际有限公司 |
吡喃葡萄糖基取代的苄基-苯衍生物的制备方法
|
WO2011039107A1
(en)
|
2009-09-30 |
2011-04-07 |
Boehringer Ingelheim International Gmbh |
Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
|
UY32919A
(es)
*
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
|
BR112012008939B1
(pt)
|
2009-10-14 |
2021-06-22 |
Janssen Pharmaceutica Nv |
Processo para a preparação de compostos úteis como inibidores de sglt2
|
US8163704B2
(en)
*
|
2009-10-20 |
2012-04-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
US8394772B2
(en)
|
2009-10-20 |
2013-03-12 |
Novartis Ag |
Glycoside derivative and uses thereof
|
ME02016B
(me)
|
2009-11-02 |
2015-05-20 |
Pfizer |
Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola
|
BR112012011733A2
(pt)
|
2009-11-13 |
2019-09-24 |
Bristol-Myers Squibb Company |
formulações de comprimido de liberação imediata
|
WO2011070592A2
(en)
*
|
2009-12-09 |
2011-06-16 |
Panacea Biotec Ltd. |
Novel sugar derivatives
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US20140088027A1
(en)
|
2010-03-30 |
2014-03-27 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
ES2559209T3
(es)
|
2010-04-14 |
2016-02-11 |
Bristol-Myers Squibb Company |
Nuevos activadores de la glucocinasa y métodos de uso de los mismos
|
EA022365B1
(ru)
|
2010-05-11 |
2015-12-30 |
Янссен Фармацевтика Нв |
Фармацевтические композиции, содержащие производные 1-(бета-d-глюкопиранозил)-2-тиенилметилбензола как ингибиторы нзпг
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
WO2012025857A1
(en)
|
2010-08-23 |
2012-03-01 |
Hetero Research Foundation |
Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
|
WO2012031124A2
(en)
|
2010-09-03 |
2012-03-08 |
Bristol-Myers Squibb Company |
Drug formulations using water soluble antioxidants
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
CN102453026A
(zh)
|
2010-10-27 |
2012-05-16 |
上海艾力斯医药科技有限公司 |
C-芳基葡糖苷衍生物、制备方法及其应用
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
TWI631963B
(zh)
*
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
RU2607480C2
(ru)
|
2011-02-01 |
2017-01-10 |
Бристол-Майерс Сквибб Компани |
Фармацевтические композиции, содержащие аминосоединение
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
WO2012109996A1
(zh)
|
2011-02-18 |
2012-08-23 |
上海璎黎科技有限公司 |
一种芳基糖苷类化合物及其制备方法和应用
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
CN102675378A
(zh)
*
|
2011-03-09 |
2012-09-19 |
天津药物研究院 |
一类含环丙烷结构的c-葡萄糖苷衍生物、其制备方法和用途
|
WO2012125622A1
(en)
|
2011-03-14 |
2012-09-20 |
Bristol-Myers Squibb Company |
Substituted adipic acid amides and uses thereof
|
CA2832938C
(en)
|
2011-04-13 |
2019-09-03 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt2
|
US8614195B2
(en)
|
2011-04-14 |
2013-12-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
CN103619862A
(zh)
|
2011-04-14 |
2014-03-05 |
诺瓦提斯公司 |
糖苷衍生物及其用途
|
US9035044B2
(en)
|
2011-05-09 |
2015-05-19 |
Janssen Pharmaceutica Nv |
L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
|
KR101576589B1
(ko)
*
|
2011-06-01 |
2015-12-10 |
주식회사 녹십자 |
Sglt2 억제제로서의 신규한 다이페닐메탄 유도체
|
WO2012163990A1
(en)
|
2011-06-03 |
2012-12-06 |
Boehringer Ingelheim International Gmbh |
Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
|
EP2717689A4
(en)
*
|
2011-06-13 |
2014-11-05 |
Panacea Biotec Ltd |
NEW SGLT HEMMER
|
CN102827122B
(zh)
*
|
2011-06-17 |
2015-01-14 |
山东轩竹医药科技有限公司 |
糖苷衍生物
|
KR101719758B1
(ko)
|
2011-06-25 |
2017-03-24 |
수안주 파마 코포레이션 리미티드 |
씨 글루코사이드 유도체
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US8815909B2
(en)
|
2011-07-18 |
2014-08-26 |
Bristol-Myers Squibb Company |
Diaminocyclohexane compounds and uses thereof
|
US8710049B2
(en)
|
2011-07-18 |
2014-04-29 |
Bristol-Myers Squibb Company |
Diaminocyclohexane compounds and uses thereof
|
JP2014530186A
(ja)
*
|
2011-09-13 |
2014-11-17 |
パナセア バイオテック リミテッド |
新規sglt阻害剤
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
WO2013178064A1
(zh)
*
|
2012-05-29 |
2013-12-05 |
广东东阳光药业有限公司 |
吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
|
US9320727B2
(en)
*
|
2012-08-30 |
2016-04-26 |
Taisho Pharmaceutical Co., Ltd |
Combinations of SGLT 2 inhibitors and antihypertensive drugs
|
EP2892896B1
(en)
|
2012-09-05 |
2016-06-29 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
|
US9499482B2
(en)
|
2012-09-05 |
2016-11-22 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
|
CN103910769B
(zh)
|
2012-12-31 |
2018-10-02 |
上海璎黎药业有限公司 |
葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
|
EP2774619B1
(de)
|
2013-03-04 |
2016-05-18 |
BioActive Food GmbH |
Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
|
US8652527B1
(en)
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
ES2969245T3
(es)
|
2013-03-14 |
2024-05-17 |
Msd Int Gmbh |
Formas cristalinas y métodos para preparar inhibidores de SGLT2
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
US9101545B2
(en)
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
CN104059042B
(zh)
*
|
2013-03-22 |
2017-02-08 |
正大天晴药业集团股份有限公司 |
C-三芳基葡萄糖苷类sglt-2抑制剂
|
EP2981269B9
(en)
|
2013-04-04 |
2023-12-06 |
Boehringer Ingelheim Vetmedica GmbH |
Treatment of metabolic disorders in equine animals
|
US20140303098A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
CN105377266A
(zh)
|
2013-04-18 |
2016-03-02 |
勃林格殷格翰国际有限公司 |
药物组合物、治疗方法及其用途
|
EP2991999B1
(en)
|
2013-04-29 |
2019-05-08 |
Mapi Pharma Limited |
Dapagliflozin lactose co-crystal
|
US10011637B2
(en)
|
2013-06-05 |
2018-07-03 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
ES2828548T3
(es)
*
|
2013-09-09 |
2021-05-26 |
Youngene Therapeutics Co Ltd |
Derivado del glucósido C-arilo, método de preparación para el mismo y aplicaciones médicas de este
|
CN104513283B
(zh)
|
2013-09-27 |
2018-01-16 |
广东东阳光药业有限公司 |
吡喃葡萄糖基衍生物及其在医药上的应用
|
CN105611920B
(zh)
|
2013-10-12 |
2021-07-16 |
泰拉科斯萨普有限责任公司 |
羟基-二苯甲烷衍生物的制备
|
KR102421234B1
(ko)
|
2013-12-17 |
2022-07-15 |
베링거잉겔하임베트메디카게엠베하 |
고양이과 동물에서 대사 장애의 치료
|
WO2015101916A1
(en)
|
2013-12-30 |
2015-07-09 |
Mylan Laboratories Ltd. |
Process for the preparation of empagliflozin
|
US9315438B2
(en)
|
2014-01-03 |
2016-04-19 |
Xuanzhu Pharma Co., Ltd |
Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
|
EP2891654B1
(en)
|
2014-01-03 |
2016-06-22 |
Xuanzhu Pharma Co., Ltd. |
Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus)
|
RS64355B1
(sr)
*
|
2014-01-23 |
2023-08-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Sglt2 inhibitori za lečenje metaboličkih poremećaja kod životinja iz roda kanin
|
US20170029398A1
(en)
*
|
2014-03-06 |
2017-02-02 |
Srinivasan Thirumalai Rajan |
Process for the preparation of (1s)-1,5-anhydro-1-c-{4-chloro-3-4[(4-ethoxyphenyl)methyl]phenyl]-glucitol and its solvate thereof
|
ES2811261T3
(es)
|
2014-04-01 |
2021-03-11 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamiento de trastornos metabólicos en animales equinos
|
CN105001213B
(zh)
*
|
2014-04-14 |
2020-08-28 |
上海迪诺医药科技有限公司 |
C-芳基糖苷衍生物、其药物组合物、制备方法及应用
|
TW201623321A
(zh)
*
|
2014-05-13 |
2016-07-01 |
韓美藥品股份有限公司 |
雙環衍生物及包含其之藥學組成物
|
EP2944311A1
(de)
|
2014-05-16 |
2015-11-18 |
BioActive Food GmbH |
Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
|
CN105085494B
(zh)
*
|
2014-05-22 |
2019-07-02 |
中国医学科学院药物研究所 |
钠糖共转运体2抑制剂、其制法和其药物组合物与用途
|
CN106714840A
(zh)
|
2014-09-25 |
2017-05-24 |
阿斯利康(瑞典)有限公司 |
用于治疗肝病的ω‑3脂肪酸和SGLT‑2抑制剂的组合
|
KR102539788B1
(ko)
|
2014-09-25 |
2023-06-07 |
베링거잉겔하임베트메디카게엠베하 |
말과 동물의 대사 장애를 예방하기 위한 sglt2 억제제와 도파민 작용제의 병용 치료
|
CN104327027B
(zh)
*
|
2014-10-14 |
2017-04-05 |
中国药科大学 |
一类新型c‑芳基葡萄糖苷sglt2抑制剂
|
EP3256482B1
(en)
*
|
2015-02-09 |
2019-11-27 |
Indoco Remedies Limited |
Process for the preparation of sglt inhibitor compounds
|
EA201791982A1
(ru)
|
2015-03-09 |
2020-02-17 |
Интекрин Терапьютикс, Инк. |
Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
|
WO2016161995A1
(en)
|
2015-04-08 |
2016-10-13 |
Zentiva, K.S. |
Solid forms of amorphous dapagliflozin
|
CN106317068A
(zh)
*
|
2015-06-23 |
2017-01-11 |
中国科学院上海药物研究所 |
一种c,o-螺环芳基糖苷类化合物及其制备和应用
|
BR112018003749B1
(pt)
|
2015-08-27 |
2023-10-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Composições farmacêuticas líquidas compreendendo inibidores sglt-2, kit de peças e processo para a produção da composição farmacêutica líquida
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
EP3362055B1
(en)
|
2015-10-15 |
2023-01-18 |
Boehringer Ingelheim International GmbH |
Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
|
KR102004488B1
(ko)
|
2015-12-11 |
2019-07-26 |
동아에스티 주식회사 |
다파글리플로진의 신규 용매화물 및 이의 제조방법
|
CN106892929B
(zh)
*
|
2015-12-17 |
2020-01-14 |
上海艾力斯医药科技有限公司 |
螺缩酮衍生物及其制备方法和应用
|
CN105693669A
(zh)
*
|
2015-12-28 |
2016-06-22 |
南昌大学 |
一种抗糖尿病化合物及其制备方法和用途
|
PT3404033T
(pt)
|
2016-01-04 |
2020-10-30 |
Jeil Pharmaceutical Co Ltd |
Derivado de c-glucósido que contém um anel de fenilo fundido ou um sal farmaceuticamente aceitável do mesmo, processo para preparação do mesmo e composição farmacêutica que compreende o mesmo
|
WO2017141202A1
(en)
|
2016-02-17 |
2017-08-24 |
Lupin Limited |
Complex of sglt2 inhibitor and process for preparation thereof
|
US9834533B2
(en)
*
|
2016-02-19 |
2017-12-05 |
Scinopharm Taiwan, Ltd. |
Process for preparing SGLT2 inhibitors and intermediates thereof
|
WO2017221211A1
(en)
*
|
2016-06-24 |
2017-12-28 |
Biocon Limited |
Process for the preparation of dapagliflozin and its solvate thereof
|
WO2018002673A1
(en)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Novel formulations of angiotensin ii receptor antagonists
|
CA3041169A1
(en)
|
2016-10-19 |
2018-04-26 |
Boehringer Ingelheim International Gmbh |
Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
|
US11020412B2
(en)
|
2017-03-16 |
2021-06-01 |
Inventia Healthcare Limited |
Pharmaceutical composition comprising dapagliflozin
|
CN110996951A
(zh)
|
2017-04-03 |
2020-04-10 |
科赫罗斯生物科学股份有限公司 |
治疗进行性核上性麻痹的PPARγ激动剂
|
KR101943382B1
(ko)
*
|
2017-09-19 |
2019-01-29 |
오토텔릭바이오 주식회사 |
Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
|
CN111989103A
(zh)
|
2018-04-17 |
2020-11-24 |
勃林格殷格翰国际有限公司 |
药物组合物、其治疗方法和用途
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
KR20200022257A
(ko)
*
|
2018-08-22 |
2020-03-03 |
동아에스티 주식회사 |
Sglt-2 억제제인 다파글리플로진 전구체의 제조방법
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
CN111840271B
(zh)
*
|
2019-04-25 |
2024-05-14 |
北京盈科瑞创新药物研究有限公司 |
一种糖苷类衍生物新用途
|
CN111471040B
(zh)
*
|
2019-01-24 |
2023-06-02 |
北京盈科瑞创新药物研究有限公司 |
一种糖苷类衍生物的合成方法及其中间体和应用
|
WO2020151621A1
(zh)
*
|
2019-01-24 |
2020-07-30 |
北京盈科瑞创新药物研究有限公司 |
化合物、其制备方法及医药用途
|
CN111471032B
(zh)
*
|
2019-01-24 |
2023-08-01 |
北京盈科瑞创新药物研究有限公司 |
一种糖苷类衍生物的合成方法及其中间体和应用
|
CN111471031B
(zh)
*
|
2019-01-24 |
2023-05-16 |
北京盈科瑞创新药物研究有限公司 |
一种糖苷类衍生物及其制备方法和应用
|
EP4021507A1
(en)
|
2019-08-30 |
2022-07-06 |
AstraZeneca AB |
Methods of treating heart failure with reduced ejection fraction with dapagliflozin
|
BR112022010385A2
(pt)
|
2019-11-28 |
2022-08-23 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inibidores de sglt-2 na secagem de mamíferos não humanos
|
MX2022010090A
(es)
|
2020-02-17 |
2022-09-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades cardiacas en felinos.
|
WO2021176096A1
(en)
|
2020-03-05 |
2021-09-10 |
Krka, D.D., Novo Mesto |
Pharmaceutical composition comprising sglt2 inhibitor
|
JP2023515668A
(ja)
|
2020-03-06 |
2023-04-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Apol-1依存性巣状分節性糸球体硬化症を治療する方法
|
WO2021214023A1
(en)
|
2020-04-22 |
2021-10-28 |
Bayer Aktiengesellschaft |
Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
|
WO2021219691A1
(en)
|
2020-04-29 |
2021-11-04 |
Astrazeneca Ab |
Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
|
EP4161912A1
(en)
|
2020-06-05 |
2023-04-12 |
KRKA, d.d., Novo mesto |
Preparation of highly pure amorphous dapagliflozin
|
WO2022022865A1
(en)
|
2020-07-27 |
2022-02-03 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
JP2023551441A
(ja)
*
|
2020-11-19 |
2023-12-08 |
ベイジン・インクリーズ・イノベーティブ・ドラッグ・カンパニー,リミテッド |
グリコシド系誘導体及びその製造方法と応用
|
KR20220091233A
(ko)
|
2020-12-23 |
2022-06-30 |
(주)국전약품 |
다파글리플로진 전구약물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
|
US20240212818A1
(en)
|
2021-04-01 |
2024-06-27 |
Astrazeneca Uk Limited |
Systems and methods for managing prediabetes with a gliflozin sodiumglucose cotransport 2 inhibitor pharmaceutical composition
|
WO2023006745A1
(en)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
AU2022318037A1
(en)
|
2021-07-28 |
2024-02-22 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
|
KR20240041966A
(ko)
|
2021-07-28 |
2024-04-01 |
베링거잉겔하임베트메디카게엠베하 |
고양이를 제외한 비인간 포유류, 특히 개에서 심장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
|
WO2023144722A1
(en)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
|
WO2023169456A1
(en)
|
2022-03-09 |
2023-09-14 |
Gasherbrum Bio , Inc. |
Heterocyclic glp-1 agonists
|
WO2023179542A1
(en)
|
2022-03-21 |
2023-09-28 |
Gasherbrum Bio , Inc. |
5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
|
WO2023198140A1
(en)
|
2022-04-14 |
2023-10-19 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
WO2023227492A1
(en)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
WO2024033288A1
(en)
*
|
2022-08-12 |
2024-02-15 |
Société des Produits Nestlé S.A. |
Salicin derivatives as inhibitors of sglt2
|